Clinical Research Master Services Agreement

CLINICAL RESEARCH MASTER SERVICES AGREEMENT

THIS MASTER SERVICES AGREEMENT ("MSA" or "Agreement"), effective as of [__/__/____] ("Effective Date"), is entered into by and between:

SPONSOR: [________________________________________], a [________] organized under the laws of [________], with principal place of business at [________________________________________] ("Sponsor").

CONTRACT RESEARCH ORGANIZATION: [________________________________________], a [________] organized under the laws of [________], with principal place of business at [________________________________________] ("CRO").

The Sponsor and CRO are collectively referred to as the "Parties" and individually as a "Party."

1. RECITALS

WHEREAS, Sponsor is developing a new drug, biological, or device (collectively, "Investigational Product") and desires to conduct one or more clinical research studies;

WHEREAS, CRO possesses expertise in clinical research services, regulatory compliance, and study management; and

WHEREAS, the Parties desire to establish a master framework for engaging CRO to provide services in support of Sponsor's clinical development program(s).

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, the Parties agree as follows:

2. SERVICES AND WORK ORDERS

2.1 Scope of Services

CRO shall provide clinical research services as described in individual Work Orders executed pursuant to this MSA. Services may include, without limitation:

☐ Study design and protocol development
☐ Investigator recruitment and site management
☐ Subject recruitment, screening, and enrollment
☐ Informed consent administration
☐ Study conduct and monitoring
☐ Data collection and case report form (CRF) management
☐ Regulatory submission support
☐ Safety monitoring and adverse event (AE) reporting
☐ Clinical supply management
☐ Quality assurance and auditing

2.2 Work Order Process

(a) Initiation. Sponsor shall issue a detailed Statement of Work ("Work Order") for each study or project. Each Work Order shall be executed and attached as an exhibit to this MSA.

(b) Work Order Contents. Each Work Order shall specify:

• Study name, protocol number, and indication
• Scope of CRO services
• Deliverables and timelines
• Budget and payment terms
• Study population and enrollment targets
• Regulatory pathway (IND, IDE, or other)
• Applicable fees and expenses

(c) Incorporation. All Work Orders shall be governed by the terms and conditions of this MSA unless expressly modified in writing by authorized representatives of both Parties.

2.3 CRO Responsibilities

CRO shall:

• Perform services in a professional, timely, and diligent manner
• Maintain qualified personnel trained in Good Clinical Practice (GCP) and applicable regulations
• Comply with all federal, state, and local laws and regulations
• Adhere to study protocols and Sponsor-approved procedures
• Provide regular status reports and deliverables as specified in Work Orders
• Maintain comprehensive study records and documentation
• Respond promptly to Sponsor inquiries and audit requests

2.4 Sponsor Responsibilities

Sponsor shall:

• Provide timely written approval of protocols, amendments, and key study documents
• Ensure adequate regulatory submissions (IND/IDE applications, safety reports, amendments)
• Maintain direct responsibility for Investigational Product safety and efficacy data
• Provide investigator's brochure, safety updates, and other required information
• Conduct or facilitate required IRB and regulatory agency communications
• Pay CRO fees and expenses as invoiced in accordance with agreed terms

3. REGULATORY COMPLIANCE

3.1 FDA IND Regulations

(a) IND Authority. Sponsor shall maintain all regulatory authority for the Investigational Product and shall submit all required IND applications (21 CFR § 312.20), amendments, and safety reports to the FDA.

(b) CRO Compliance. CRO shall comply with all IND regulations (21 CFR Part 312) including:

• Protocol and informed consent adherence
• Adverse event and serious adverse event (SAE) reporting timelines
• Study termination procedures
• Subject safety tracking and expedited reporting

(c) IDE Regulations. For device studies subject to 21 CFR Part 812 (IDE), CRO shall comply with investigational device exemption requirements and report device defects to Sponsor within 24 hours of discovery.

3.2 Good Clinical Practice Standards

(a) ICH E6(R3) Compliance. CRO shall conduct all studies in accordance with the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, including ethical conduct, subject protections, and quality standards.

(b) Training Documentation. CRO shall maintain evidence of GCP training for all study personnel with access to protocols, informed consent forms, or subject data, with training refreshed annually.

(c) Study Monitoring. CRO shall establish a risk-based monitoring plan and conduct routine source data verification to ensure protocol compliance, data accuracy, and subject safety.

3.3 21 CFR Part 11 Electronic Records

(a) System Validation. CRO shall ensure all electronic systems used to capture, process, store, or transmit study data comply with 21 CFR Part 11 requirements for electronic signatures, audit trails, and data integrity.

(b) Audit Trails. CRO shall maintain complete, unalterable audit trails for all electronic data modifications, including user identification, timestamp, and reason for change.

(c) Security Measures. CRO shall implement appropriate access controls, encryption, and data backup procedures to protect study integrity and subject data.

3.4 HIPAA Compliance

CRO shall comply with all applicable provisions of the Health Insurance Portability and Accountability Act (HIPAA) as amended, including:

• Protection of individually identifiable health information (PHI)
• Breach notification requirements (45 CFR §§ 164.400-164.414)
• Business Associate obligations if applicable
• Subject authorization for use and disclosure of PHI in research

4. PROTOCOLS AND STUDY CONDUCT

4.1 Protocol Compliance

CRO shall:

• Conduct all studies in strict accordance with the current Sponsor-approved protocol and any amendments
• Notify Sponsor immediately of any protocol deviations and implement corrective measures
• Report amendments to the FDA and IRBs as required
• Maintain protocol documentation and communicate study status at agreed intervals

4.2 Informed Consent

CRO shall:

• Obtain informed consent from all subjects using the IRB-approved informed consent form (ICF) prior to any study procedures
• Document subject consent signature and date
• Provide each subject with a copy of the signed ICF
• Report any subject concerns or questions regarding the study to Sponsor

4.3 Data Standardization (CDISC)

CRO shall:

• Capture clinical trial data in accordance with Clinical Data Interchange Standards Consortium (CDISC) standards (e.g., SDTM, ADaM) when specified in the Work Order
• Provide data in electronic format suitable for submission to regulatory agencies
• Maintain data dictionaries and validation rules to ensure consistency and traceability

5. SUBJECT SAFETY AND ADVERSE EVENTS

5.1 Safety Reporting Obligations

CRO shall:

• Establish procedures to identify, document, and report all adverse events (AEs) in accordance with the protocol and IND/IDE regulations
• Report serious adverse events (SAEs) to Sponsor within 24 hours of discovery
• Provide written AE reports within timelines specified in the Work Order or protocol

5.2 Subject Injury—Non-Negligent Injury Clause

(a) Sponsor Responsibility. Sponsor shall establish and maintain subject injury insurance or demonstrate financial responsibility for non-negligent subject injuries as required by FDA regulations and relevant state law.

(b) CRO Disclaimer. CRO shall not be responsible for injury or death to subjects resulting from non-negligent risks inherent to the Investigational Product or the study procedure itself. Sponsor shall be solely responsible for subject injury claims arising from non-negligent causes.

(c) CRO Negligence Exception. Nothing herein shall limit CRO's liability for injuries caused by CRO's gross negligence, willful misconduct, or violation of applicable law or GCP standards.

5.3 Safety Holds

CRO shall immediately comply with Sponsor-initiated study holds or suspensions due to safety concerns and shall not resume activities until written authorization from Sponsor is received.

6. CONFIDENTIAL INFORMATION AND DATA PROTECTION

6.1 Definition of Confidential Information

"Confidential Information" means all non-public technical, business, and regulatory information disclosed by one Party to the other, including protocols, data, scientific findings, manufacturing processes, and business terms.

6.2 Obligations of Confidentiality

CRO shall:

• Restrict access to Confidential Information to employees and contractors with a need to know
• Implement reasonable security measures to protect Confidential Information
• Not disclose Confidential Information to third parties without prior written consent
• Maintain Confidential Information for [5] years after termination of the Agreement
• Return or certify destruction of Confidential Information upon Sponsor request

6.3 Permitted Disclosures

CRO may disclose Confidential Information:

• As required by law, regulation, or court order, provided CRO provides prompt notice to Sponsor to allow Sponsor to seek protective measures
• To IRBs, regulatory agencies, and trial participants as necessary to conduct the study or comply with legal obligations
• To subcontractors under written confidentiality obligations no less protective than this Agreement

6.4 Subject Data and Privacy

CRO shall:

• Maintain subject data in a secure, access-controlled environment
• De-identify subject data for analysis or reporting unless otherwise approved by Sponsor
• Comply with HIPAA and all applicable data protection laws (including GDPR if applicable)
• Not use subject data for any purpose outside the scope of the study without written consent

7. PUBLICATION RIGHTS AND SPONSOR REVIEW

7.1 Publication Restriction Period

CRO shall not publish, present, or disclose any study data, results, or findings without prior written consent of Sponsor. Sponsor shall have the right to review and comment on any proposed publication within [30] days of submission.

7.2 Sponsor Pre-Review

(a) Submission. Before any public presentation or manuscript submission, CRO shall provide Sponsor with a draft copy at least [45] calendar days in advance.

(b) Sponsor Rights. Sponsor may request:

• Corrections for factual accuracy
• Deletion of Confidential Information or trade secrets
• Delay of publication for [90] days to allow Sponsor to file patent applications
• Removal of Sponsor's Confidential Information

(c) Resolution. If the Parties cannot agree on publication content, Sponsor's decision shall prevail regarding deletion of proprietary information and patent-sensitive data.

7.3 Authorship and Acknowledgments

CRO shall:

• Include Sponsor and Sponsor's personnel as authors or acknowledged contributors as appropriate
• Provide Sponsor with authorship order and acknowledgment language for approval
• Register all publications with Sponsor within 30 days of publication

8. INTELLECTUAL PROPERTY

8.1 Sponsor IP

All intellectual property, including patents, copyrights, and trade secrets, related to the Investigational Product, protocols, study data, and regulatory submissions shall be owned solely by Sponsor.

8.2 CRO IP

CRO shall retain ownership of pre-existing tools, methodologies, and know-how ("CRO Background IP"). CRO hereby grants Sponsor a non-exclusive, royalty-free license to use CRO Background IP solely for purposes of this study.

8.3 Joint IP

Any inventions or works created jointly by Sponsor and CRO personnel ("Joint IP") shall be owned jointly; either Party may use Joint IP without accounting to the other, except that neither Party shall license Joint IP to a third party without the other Party's written consent.

8.4 Work Product

All study protocols, case report forms, statistical analysis plans, clinical study reports, and other study work product shall be owned by Sponsor upon payment of all fees.

9. INDEMNIFICATION

9.1 CRO Indemnification

CRO shall indemnify, defend, and hold harmless Sponsor from any claims, damages, liabilities, and costs arising from:

• CRO's breach of this Agreement
• CRO's negligence, gross negligence, or willful misconduct
• CRO's violation of applicable law or regulatory requirements
• CRO's infringement of third-party intellectual property rights
• Injury or death to third parties caused by CRO's actions or omissions in performing services

9.2 Sponsor Indemnification

Sponsor shall indemnify, defend, and hold harmless CRO from any claims arising from:

• Non-negligent injuries or adverse effects of the Investigational Product
• Sponsor's breach of this Agreement
• Sponsor's violation of applicable law or regulatory requirements
• Claims arising from Sponsor's use of study data or results

9.3 Indemnification Conditions

Indemnified Party shall:

• Provide prompt written notice of any claim
• Cooperate in defense of the claim
• Allow indemnifying Party to control the defense and settlement

10. INSURANCE AND LIABILITY

10.1 CRO Insurance

CRO shall obtain and maintain:

• Professional liability insurance ($[__________] minimum coverage)
• General liability insurance ($[__________] minimum coverage)
• Cyber liability and data breach insurance ($[__________] minimum coverage)
• Workers' compensation insurance as required by law

CRO shall provide certificates of insurance to Sponsor upon request and ensure coverage remains in effect throughout the Agreement term.

10.2 Sponsor Insurance

Sponsor shall maintain subject injury insurance or equivalent financial responsibility as required by FDA regulations and applicable law.

10.3 Limitation of Liability

EXCEPT FOR BREACHES OF CONFIDENTIALITY, INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS, OR INDEMNIFICATION OBLIGATIONS, NEITHER PARTY SHALL BE LIABLE FOR INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS OR BUSINESS INTERRUPTION, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

11. TERM AND TERMINATION

11.1 Term

This MSA shall commence on the Effective Date and continue for a period of [3] years, unless earlier terminated in accordance with its terms. It shall automatically renew for successive [1]-year periods unless either Party provides written notice of non-renewal at least [60] days before the expiration of the then-current term.

11.2 Termination for Convenience

Either Party may terminate this MSA for convenience upon [90] days' written notice to the other Party. Termination shall not affect any Work Orders in progress unless specified in the termination notice.

11.3 Termination for Cause

Either Party may terminate this MSA immediately upon written notice if the other Party:

• Materially breaches this Agreement and fails to cure within [30] days of written notice
• Becomes insolvent or subject to bankruptcy proceedings
• Violates applicable law or regulatory requirements in a material manner
• Engages in fraud or gross negligence

11.4 Effects of Termination

Upon termination:

• CRO shall immediately cease providing services except as necessary to wind down ongoing studies
• CRO shall transfer all study records and data to Sponsor
• CRO shall cooperate in transitioning services to a successor CRO or Sponsor
• Payment obligations for services rendered shall survive termination
• Confidentiality and indemnification obligations shall survive indefinitely

11.5 Study Continuity

Termination of this MSA shall not terminate ongoing Work Orders unless specified in the termination notice. CRO shall cooperate to ensure continuity of study operations and transfer of records.

12. COMPENSATION AND PAYMENT

12.1 Fees

CRO shall invoice Sponsor for services as specified in each Work Order. Fees shall include [specific deliverables, timelines, and payment milestones to be detailed in Work Order].

12.2 Expenses

CRO shall be reimbursed for reasonable, documented expenses approved in advance by Sponsor, including [travel, site costs, shipping, laboratory testing]. CRO shall provide itemized receipts or invoices supporting all expense claims.

12.3 Invoice and Payment

(a) CRO shall submit invoices [monthly/upon completion of deliverables] detailing services rendered and expenses incurred.

(b) Sponsor shall pay invoices within [30] days of receipt.

(c) Late payments shall accrue interest at [__]% per annum or the maximum rate permitted by law, whichever is less.

12.4 Changes to Scope

Any changes to the scope of services, budget, or timeline shall require a written Work Order amendment executed by authorized representatives of both Parties before CRO incurs additional costs.

13. REPRESENTATIONS AND WARRANTIES

13.1 Sponsor Representations

Sponsor represents and warrants that:

• It has authority to enter into this Agreement
• It shall obtain all necessary IRB approvals before initiating studies
• The Investigational Product information provided is accurate and complete
• It shall comply with all FDA regulations and reporting requirements
• It shall maintain subject injury insurance or equivalent financial responsibility

13.2 CRO Representations

CRO represents and warrants that:

• It has authority to enter into this Agreement
• It possesses necessary licenses, certifications, and qualifications to perform services
• It shall comply with GCP standards and all applicable regulations
• Services shall be performed in a professional, workmanlike manner
• It shall maintain appropriate cyber security measures and business continuity plans

14. COMPLIANCE AND AUDIT

14.1 Regulatory Audits

CRO shall:

• Permit FDA, IRBs, and other regulatory authority inspections and audits of study sites and records
• Cooperate fully with regulatory investigations
• Provide documentation and personnel for interview as requested
• Implement corrective actions based on audit findings

14.2 Sponsor Audits

Sponsor may, at its expense, audit CRO's performance, records, and compliance with this Agreement upon [15] days' written notice. CRO shall provide reasonable access to records, systems, and personnel.

14.3 Subcontractor Audits

CRO shall ensure subcontractors comply with the terms of this Agreement and permit Sponsor to audit subcontractor records.

15. DISPUTE RESOLUTION

15.1 Escalation

Any dispute shall first be escalated to senior management representatives of both Parties for good-faith negotiation within [30] days.

15.2 Mediation

If negotiation fails, the Parties agree to submit the dispute to non-binding mediation before pursuing litigation.

15.3 Governing Law

This Agreement shall be governed by and construed in accordance with the laws of [State/Country], without regard to conflict of law principles. The Parties exclude application of the United Nations Convention on Contracts for the International Sale of Goods.

15.4 Venue and Jurisdiction

Each Party consents to the exclusive jurisdiction and venue of the state and federal courts located in [County/City, State] for any legal proceedings arising under this Agreement.

16. GENERAL PROVISIONS

16.1 Entire Agreement

This Agreement, including all attached Work Orders and exhibits, constitutes the entire agreement between the Parties and supersedes all prior negotiations, understandings, and agreements.

16.2 Amendments

This Agreement may be amended only by written document signed by authorized representatives of both Parties.

16.3 Severability

If any provision is held invalid or unenforceable, the remaining provisions shall continue in full force and effect, and the invalid provision shall be modified to the minimum extent necessary to make it enforceable.

16.4 Waiver

No waiver of any provision shall be effective unless in writing. Waiver of any breach shall not constitute waiver of any subsequent breach.

16.5 Notices

All notices shall be in writing and delivered personally, by overnight courier, or by certified mail to the addresses specified below. Notices shall be effective upon receipt.

For Sponsor:
[________________________________________]
[________________________________________]
Attn: [________________]

For CRO:
[________________________________________]
[________________________________________]
Attn: [________________]

16.6 Independent Contractors

CRO is an independent contractor. Nothing in this Agreement creates a partnership, joint venture, or employment relationship.

16.7 Counterparts and Electronic Signatures

This Agreement may be executed in counterparts and by electronic signature (PDF, DocuSign, etc.), each of which shall constitute an original and all of which together shall constitute one agreement.

16.8 Assignment

Neither Party may assign this Agreement without the prior written consent of the other Party, except that Sponsor may assign to an affiliate or successor entity upon written notice.

17. EXHIBITS AND WORK ORDER TEMPLATE

Exhibit A: Work Order Template

WORK ORDER [__]

STUDY NAME: [________________________________________]

PROTOCOL NUMBER: [________________]

EFFECTIVE DATE: [__/__/____]

A. SCOPE OF SERVICES

CRO shall provide the following services:

☐ Study design and protocol development
☐ Site selection and recruitment ([____] investigator sites)
☐ Subject recruitment and screening
☐ Informed consent administration
☐ Study conduct and monitoring
☐ Safety assessment and AE reporting
☐ Data management and CDISC standardization
☐ Statistical analysis plan development
☐ Clinical trial report preparation
☐ Regulatory submission support
☐ Other: [________________________________________]

B. DELIVERABLES AND TIMELINES

C. ENROLLMENT AND STUDY POPULATION

Target Enrollment: [________] subjects

Study Duration: [________] months

Study Population: [________________________________________]

D. REGULATORY PATHWAY

☐ IND (FDA)
☐ IDE (FDA)
☐ EMA (EMEA)
☐ Other: [________________]

IND Number: [________________] IDE Number: [________________]

E. BUDGET AND PAYMENT

Total Project Budget: $[__________]

Payment Schedule:

• Initiation: $[__________] ([____]% of total)
• Interim Payments: $[__________] per [month/milestone]
• Completion: $[__________] ([____]% of total)

Expense Cap: $[__________] (CRO may not exceed without written authorization)

Payment Terms: Net [30] days from invoice

F. REPORTING AND COMMUNICATION

Progress Reports: [Monthly/Quarterly] to [Contact Name]

Key Contacts:

Sponsor: [________________________________________]
CRO: [________________________________________]

G. SIGNATURE

This Work Order is executed effective as of the date first written above and shall be governed by the terms of the Master Services Agreement dated [__/__/____].

Exhibit B: Protocol Deviation Report Template

PROTOCOL DEVIATION REPORT

Study: [________________________________________]

Protocol Version: [________]

Report Date: [__/__/____]

Subject ID: [________]

Deviation Description: [________________________________________]

Date of Deviation: [__/__/____]

Reason for Deviation: [________________________________________]

Corrective Action Taken: [________________________________________]

Impact on Data Integrity: ☐ None ☐ Minor ☐ Major

Reported to FDA: ☐ Yes ☐ No

Signature: _________________________ Date: [__/__/____]

Exhibit C: Audit Readiness Checklist

AUDIT READINESS CHECKLIST

☐ All investigator files complete and up-to-date
☐ Subject consent forms signed and dated
☐ Source documents match case report forms
☐ Protocol deviations documented and communicated
☐ Safety reports submitted within required timelines
☐ Personnel training records current
☐ Equipment calibration and maintenance records available
☐ Electronic systems validated (21 CFR Part 11 compliant)
☐ Audit trails reviewed and verified
☐ Mock audit completed within past [12] months
☐ Corrective actions from prior audits closed

SOURCES AND REFERENCES

• FDA:
• 21 CFR Part 312 (IND Regulations)
• 21 CFR Part 812 (IDE Regulations)
• 21 CFR Part 11 (Electronic Records)

• FDA Guidance: "Oversight of Clinical Investigations" (https://www.fda.gov/)

• ICH Guidance:

• ICH E6(R3) Good Clinical Practice Guidelines

• HIPAA:

• 45 CFR §§ 164.400-164.414 (Breach Notification Rule)

• CDISC Standards:

• Study Data Tabulation Model (SDTM)
• Analysis Data Model (ADaM)

[END OF MASTER SERVICES AGREEMENT]